首页> 美国卫生研究院文献>Pharmaceuticals >Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis
【2h】

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis

机译:基于药用大麻的杂志制剂的临床证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment that meets quality standards to ensure the quantities of its main components, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Furthermore, suppliers must have a clear indication of its use in the patient before prescription. This review shows the published evidence regarding the clinical use of medicinal cannabis magistral preparations in the management of post-chemotherapy nausea and vomiting, neuropathic pain in multiple sclerosis, and anorexia and cachexia in patients with HIV.
机译:大麻被广泛用作千年的药用植物;然而,与其主要成分相关的研究是在1960年首次进行的。随后,实验室已经产生了与其活性生物学特性有关的新组分和结构。已批准大麻药用使用的国家施加了管理其临床和科学用途的法规。一种施用药用大麻的手段是通过杂志制剂制备,必须具有医疗处方,并在满足质量标准的建立中制备,以确保其主要成分的数量,例如四氢萘酚(THC)和大麻(CBD)。此外,供应商必须在处方前明确指出其在患者身上的用途。本综述显示了有关医药大麻杂志制剂在化疗后恶心和呕吐的呕吐,多发性硬化症的神经性疼痛的临床应用中发表的证据,以及艾滋病毒患者的厌食症和恶病症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号